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Abstract
Background: Feline immunodeficiency virus (FIV) is a lentivirus associated with AIDS-like illnesses in cats and has been used
as a model for the study of human immunodeficiency virus (HIV). A feature of HIV and FIV infection is the continually
increasing divergence among viral isolates between different individuals, as well as within the same individuals.
Methodology/Principal Findings: The goal of this study was to determine the phylogenetic patterns of viral isolates
obtained within the United States (U.S.) by focusing on the variable, V3-V4, region of the FIV envelope gene.
Conclusions/Significance: Data indicate that FIV, from within the U.S., localize to four viral clades, A, B, C, and F. Also shown
is the geographic isolation of strains where clade A and clade B are found predominately on the west coast; however, clade
B is also found throughout the U.S. and represents the predominant clade. This study presents a complete and conclusive
analysis of FIV isolates from within the U.S. and may be used as the essential basis for the development of an effective multi-
clade vaccine.
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Introduction
Feline immunodeficiency virus was first isolated from a cat
exhibiting an immunodeficiency-like syndrome [1]. This isolate
from petaluma, california was designated the petaluma strain, and
has become one of the most common laboratory strains used for
research investigating lentiviral pathogenesis, antiviral chemother-
apy design and testing, and for developing vaccine strategies as a
small animal model for HIV [2,3,4,5,6,7]. Further investigation
lead to the discovery that FIV had a wide range of host species and
was prevalent in animals at a rate of 1% to 14%, depending on the
country, age, gender, and risk of exposure [1,8,9,10,11,12,13].
Sick animals are two to three times more likely to be infected with
FIV than clinically healthy cats [9].
FIV, like the primate lentiviruses, readily infect CD4
+ T [14].
However, fiv has been found to infect and replicate in a wide
range of host cells including: CD8
+ T lymphocytes, macrophages,
astroglial cells, and kidney cells [12,15,16,17]. Although not fully
understood, the receptor for FIV is believed to be CD9 [18];
whereas, SIV and HIV use the CD4 receptor as well as the
coreceptors CCR5 and CXCR4 for entry [19,20]. FIV results in a
disease progression similar to HIV and SIV and is associated with
symptoms of immunodeficiency: weight loss, chronic lesions,
opportunistic infections, and neurological abnormalities [21]. Due
to the similarities in FIV and HIV pathogenesis, fiv has become as
the only small animal non-primate model for the study of HIV
disease, therapy, and prophylaxis.
As in HIV, FIV has a large amount of genetic variation and can be
grouped into clades based on the nucleotide sequence and geographic
location [22,23]. This vast amount of genetic variation has lead to an
almost insurmountable impediment [24]. Studies on FIV in
countries, such as Japan, Italy, and Brazil have been shown to
consist primarily of one clade of endogenous FIV. However, FIV in
Australia, New Zealand, Canada, and Japan has been shown to
consist of multiple clades [22,23,24,25,26,27,28,29,30,31]. This large
amount of genetic variation in the u. S. Is also complicated by the
existence of recombinant viral strains [32,33].
Recently, a dual clade vaccine (Fort Dodge City) was advanced
into commercial production. This vaccine is composed of two
distinct clades, A and D [34]. As the amount of genetic variation in
the viral challenge will be inversely proportional to the efficacy of
the vaccine, it was of interest to examine the phylogenetic
variation of FIV within the United States.
Thirty-six FIV isolates were obtained from infected domestic
and feral cats in eight U.S. cities. The proviral DNA was used to
amplify the V3-V4 envelope gene for phylogenetic analyses as
compared to other known U.S. isolates. The phylogenetic analyses
indicate that the U.S. is populated with a much greater divergence
of FIV than previously thought. Data indicate high levels of
divergence across the country and within any one city. The
resulting mixture of viral clades has, as expected, resulted in the
continuous evolution of recombinant virus strains.
Materials and Methods
Cells and DNA isolation
FIV in vivo infection within PBMCs was confirmed by antibody
ELISA. Whole blood was collected in EDTA (K3) tubes and
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tested positive for FIV by in vitro assay were voluntarily submitted
from the following hospitals: Stanford University Feral Cat
Association, Stanford, CA, Dunstable Animal Clinic, Dunstable,
MA, Oregon Feral Cat Coalition, Portland, OR, Homer
Veterinary Clinic, Homer, AK, Betts Sanderson, San Ramon,
CA, Tree House Animals, Chicago, IL, and Brazos Feral Cat
Association, College Station, TX. PBMCs were processed using a
BSL2 isolation cabinet. Lymphocytes were isolated from whole
blood using a 5-fold volume of ACK lysis buffer (0.15 M NH4Cl,
10 mM KHCO3, 0.1 mM EDTA, pH 7.4) and washed 1 time
with PBS. Genomic DNA (gDNA) that contained the FIV
proviral DNA was isolated from the lymphocytes using a
mammalian genomic DNA Isolation miniprep kit (Sigma, St.
Louis, MO). The gDNA was stored at –20uC until it was
amplified by PCR.
PCR
gDNA containing integrated proviral FIV DNA isolated from
lymphocytes was used as the template for PCR. Briefly, the envelope
V3-V4 genes were amplified by nested PCR as previously described
[35]. The primary amplification of the V3-V4 envelope region was
performed using the primers 6785F (59-GCGCAAGTAGTGTG-
GAG-39) and 8842R (59- GCTTCATCATTCCTCCTCTT-39).
PCRs were performed in a total volume of 50 ul containing 100 ng
gDNA, 100 nM final concentration of each primer, 200 uM of each
Figure 1. Rooted-quartet puzzling tree of the FIV envelope V3–V4 nucleotide sequence alignment. Support for the internal branches of
the rooted tree topology is shown in percent of 100 puzzling steps.
doi:10.1371/journal.pone.0012004.g001
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parameters were used to amplify the genes using a GeneAmp 2400
(Perkin Elmer):94uC for 5 min. followed by 5 cycles of 94uCf o r6 0s ,
53uCf o r6 0s ,a n d7 2 uC for 2 min., and finally 30 cycles of 94uCf o r
15 s, 53uC for 45 s, and 72C for 2 min. The annealing step was
increased by 0.1uC per cycle for 30 cycles. The reaction was held at
72uC for 15 min. followed by 4uC. The following primers were used
to amplify the V3–V4 region of the envelope in a secondary PCR
reaction: 7316F (59-ATACCAAAATGTGGATGGTG-39)a n d
7866R (59-CAAGACCAATTTCCAGCAAT-39). The secondary
PCR mixture was identical to the primary PCR with the exception
that 5 ul of the primary PCR was used as the template. The thermal
cycling parameters for the secondary PCR was identical to the
primary PCR with the exception that the extension step was
shortened to 72uC for 1 min. The annealing step was increased by
0.1uC per cycle for the 30 cycles. The reaction was held at 72uCf o r
7m i n . f o l l o w e d b y 4 uC. DNA isolated from FIV negative
lymphocytes served as negative controls.
DNA sequencing
The PCR products were purified using a Genelute PCR Clean-
up kit (Sigma, St. Louis, MO). The PCR products were adjusted to
5 ng/ul and 2 ul was used for direct sequencing. DNA sequencing
was performed using BigDye Terminator v3.1. The following
thermal cycling steps were used for extension of the V3–V4
product for 45 cycles: 96uC for 10 sec, 50uC for 5 sec and 60uC
for 4 min. After purification of the product by ethanol precipita-
tion or spin-column purification protocol, the samples were sent to
the Gene Technologies Core Facility for DNA sequencing and
analyzed using the ABI 3100 Automated Sequencer (Department
of Biology, Texas A&M University). The products were sequenced
in triplicate using the forward and reverse PCR primers. A
Figure 2. Maximum parsimony tree based on the nucleotide sequence of the V3–V4 envelope region. Values represent statistical
bootstrap analysis based on 500 replicates. The tree was created using tree-bissection-reconnection and polytomies were created if maximum branch
length is zero.
doi:10.1371/journal.pone.0012004.g002
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in the Sequencher program.
Sequence alignment and phylogenetic analyses
Sequences included in the phylogenetic analysis were
obtained from this study and from previous GenBank entries
(Table S1). Sequences were aligned by using the Clustal X
program [36]. All aligned sequences were then inspected
manually to correct for apparent mistakes. Positions containing
gaps or ambiguously aligned positions were removed from the
datasets. Phylogenetic trees were created using the program
PAUP* 4.0b8 (Sinauer Associates, Sunderland Mass.) and
T r e e P u z z l e5 . 0( F r e eS o f t w a r eF oundation, Inc. Boston, MA).
Maximum parsimony analyses are performed in order to
establish evolutionary relationships based on the least number
o fs t e p st oe x p l a i nt h et r e e .T h ef ollowing parameters were used
for maximum parsimony of envelope V3–V4 nucleotide
sequences: i) 572 total characters, ii) all characters were
weighted equally, iii) 215 characters were constant, iv) 277
parsimony informative characters, v) random addition of
sequence, vi) 500 bootstrap replicates. Maximum likelihood
analyses attempt to infer the evolutionary tree that has the
highest probability of observing the data. Maximum likelihood
analysis continually compares trees and chooses the one with the
best score. The following parameters were used for maximum
likelihood puzzling tree based on nucleotide sequences: i) 575
total characters, ii) 163 constant characters, iii) 395 site patterns,
iv) HKY model of substitution, v) expected transition/transver-
sion ratio =1.75, vi) pyrimidine transition/purine transition
ratio =0.41, vii) 1215450 quartets were analyzed with 17686
Figure 3. Log/Det paralinear distance tree based on the predicted amino acid sequence of the V3–V4 envelope region. Values
represent statistical bootstrap analyses with full heuristic search at 1000 replicates. Tree-bissection-reconnection algorithm was used and zero branch
lengths were not collapsed. All ties were broken at random.
doi:10.1371/journal.pone.0012004.g003
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statistical analysis. Distance analyses compare pairwise charac-
ters in a data set column and determine the degree of
d i f f e r e n c e s .D i s t a n c et r e e so ft h en u c l e o t i d es e q u e n c ed a t aw e r e
established using the following parameters: i) 572 characters, ii)
distance measure = LogDet/paralinear, iii) ties were broken at
random, iv) 1000 bootstrap replicates were used for statistical
analysis.
The maximum likelihood phylogenetic analysis of the amino acid
sequence was established using the following parameters: i) 290
characters, ii) 229 site patterns, iii) 13 constant site patterns, iv) model
of substitution = JTT, v) 1663740 quartets were analysed with
146464 unresolved quartets, vi) 1000 puzzling steps were used for
statistical analysis. The following parameters were used in creating the
maximum parsimony tree of the amino acid alignment: i) 298
characters, ii) all characters have equal weight, iii) 109 constant
characters with 130 parsimony-informative characters, iv) gaps were
treated as missing, v) 500 bootstrap replicates with full heurisistic
search was used for statistical analysis. The following parameters were
used to establish the distance phylogenetic tree based on the amino
Figure 4. Quartet-puzzling tree based on approximate maximum likelihood values for the predicted envelope V3–V4 amino acid
sequences. Bootstrap analysis was based on 1000 puzzling steps and values less than 50 were collapsed creating polytomies.
doi:10.1371/journal.pone.0012004.g004
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neighbor-joining search at 1000 replicates was used for statistical
analysis, iii) ties were broken at random, iv) distance measure = mean
character difference. All trees were viewed in treev32 (Roderick M.
Page, 2001).
Results
In order to define the level of FIV genetic diversity in the U. S.,
an epidemiological survey of FIV envelope sequence diversity was
conducted. Blood specimens were obtained from FIV infected cats
as a result of requests sent to Veterinarians and researchers.
Genomic DNA was isolated and nested PCR was used to amplify a
predicted 550 bp segment of the envelope gene that encodes the
viral surface protein. This fragment spans the third and fourth
variable regions. The PCR products ranged in size from 443 bp to
555 bp. The average size of the isolates, which clustered to the A,
B, and F branches were 501.0 bp 610.34, 495.5610.60, and
521.468.02, respectively. Table S2 shows the sample descriptions
and clade analysis as obtained from the current study as well as
from previously published studies [24,31]. Many of the sequences
were classified using a heteroduplex mobility assay, which
correlates very well with sequence analyses [24].
A rooted-quartet-puzzling tree was used to analyze the sequence
variation and clustering of the viral isolates as compared to
sequences of previously published isolates. Tree puzzling uses
maximum likelihood parameters and 100 puzzling steps were used
to estimate statistical probabilities (Fig. 1). Polytomies were created
if statistical probabilities were below 50%. As can be seen in
figure 1 all of the TX isolates clustered to a unique and
Figure 5. Maximum parsimony tree based on the predicted amino acid sequence of the V3–V4 envelope region. Values represent
statistical bootstrap analysis based on 500 replicates. The tree was created using tree-bissection-reconnection and polytomies were created if
maximumbranch length is zero.
doi:10.1371/journal.pone.0012004.g005
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published sequence, USTXmtex03, clustered to the very same
clade, as well as an isolate from Oregon, OR2. Figure 1 also shows
that many of the Oregon, California, and Illinois samples grouped
to the A clade. Isolates IL2, IL3, IL4, IL5. IL7, IL8, MA1, MA2,
MA3, MA4, MA5, MA6, MA7, CA1-2, CA2-2, and CA2-1
grouped to the B clade. This very same pattern was supported by
the least stringent of all analyses, maximum parsimony and is
illustrated in figure 2. Statistical support for maximum parsimony
was obtained by 500 bootstrap replicates. Statistical analysis
supported the unique F clade, as well as the clustering of the
remaining isolates to the A and B clades (Fig. 2). Finally, using
sequence data, a Log/Det paralinear distance tree was created
(Fig. 3). The statistical values represent 1000 bootstrap replicates
with full heuristic search (Fig. 3). This data was in complete
agreement with the previous two methods of phylogenetic analysis
used here and shows strong statistical support for the grouping of
the isolates into clades (Fig. 3).
Phylogenetic analyses were also performed using amino acid
alignments. Figure 4 shows a quartet-puzzling tree based on the
predicted amino acid sequence alignment. Statistical values were
based on 1000 puzzling steps. Values less than 50 resulted in the
collapse of the branch resulting in polytomies. Due to the
complexity inherent to phylogenetic analysis based on amino acid
alignments, many of the branches formed using nucleotide
sequence data were collapsed (Fig. 4). Also, several of the isolates
were not in agreement with previous analyses. For example, clades
B, E and F were collapsed creating one large branch (Fig. 4).
Isolate CA2-1, which had been previously grouped with the B
clade, was grouped with the D clade (Fig. 4). However, when the
amino acid alignments were subjected to analysis by maximum
parsimony, the resulting tree was in agreement with the earlier
nucleotide sequence data (Fig. 5). Again, the F clade contained the
isolates OR2 and USTXmtex03 (fig. 5).
Figure 6 represents the geographic location and clade of the viral
isolates, as well as the number of samples analyzed. Eleven states had
clade A viral isolates, 20 states had clade B isolates, and only one state
had clade C isolates (Fig. 6). Many of the states, such as Texas,
Oregon, California, Illinois, and Minnesota had multiple clades
(Fig. 6). Also, isolates from Oregon localized to 3 different clades and
indicate a high level of viral heterogeneity. Table 1 shows the average
percent nucleotide identity of the viral isolates as compared to
previously published and characterized viral isolates (Table 1). The
isolates, which grouped to the A and B clades by phylogenetic
analysis, show levels of sequence divergence within the limitations of
classification, 15.0%. There is one exception, isolate CA2-1 does not
fall into the limits of classification to the B clade, yet is grouped with
the B clade in 4 of 5 phylogenetic analyses (Table 1). Most of the
isolates which group to the F clade do not fall within the limits for the
previously classified clades A–E and represents the recently
established clade F (Table 1) [35].
Discussion
A major obstacle in generating a vaccine effective against FIV
infection is the already large, and growing, genetic diversity among
viral antigenic determinants, especially in regard to the area
responsible for viral neutralization, the envelope. FIV vaccine
researchers hope to circumvent this daunting task and still
establish immunity against natural infection. However, little is
known about the absolute sequence divergence of FIV. This limits
researchers in their ability to develop and test vaccines capable of
protection against natural challenge. The heteroduplex mobility
assay (HMA) was developed as a rapid and reliable method for
classifying HIV-1 env genes into clades and for inferring intraclade
diversity. However, there are well over 200,000 HIV-1 sequences
available through the National Center for Biotechnology Infor-
mation, while only 646 sequences for FIV are available. Since the
phylogenetic variation of HIV-1 has been well elucidated, HMA
may be an appropriate means of determining genetic variation
within a geographic region. However, in the case of FIV, much
more sequence information is necessary to fully understand the
similar diversity of FIV and HIV.
The first FIV infectious clones were derived from California
isolates that represent clade A [37,38]. Therefore, due to the
advantages of using an infectious clone over a field isolate or a cell
culture adapted isolate, many of the current vaccine studies are
based on protection against a FIV clade A infection. However, the
data from this study indicate that FIV sequence divergence may be
greater than previously shown [11,24,31]. It is interesting to note
that the majority of the isolates sequenced on the west coast, 24 of
34, were of clade A; whereas, the east coast isolates are, with the
exception of one isolate, all of clade B (Fig. 6).
Figure 6. The clades of FIV isolates from various regions across the U.S.A. Data was obtained directly from this study as well as previously
published studies. Clades and the number of viral isolates analyzed are shown as subscript values.
doi:10.1371/journal.pone.0012004.g006
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difficult to define and is sometimes composed of sequences that do
not fall into D or E clades [24]. The B clade had been previously
broken into three clusters extending from a central stem. However,
with the addition of the Texas isolates, the B clade is broken into
two clearly definable and unique clades, the B clade and the TX
clade. These TX isolates are on average greater than 15%
divergent from the nearest clade, clade B. Due to the intense scope
of the B clade, the TX clade has been established as a new viral
clade, clade F [35].
Phylogenetic analyses and distance calculations presented in this
study indicate that the viral divergence of FIV within the U.S.A.
localize to 4 clades. Clades A and B are found throughout the
U.S.A. and may represent the predecessor viruses. It is possible,
that through isolation and genetic drift, the F clade may have been
derived from one of the predecessor isolates. It is also possible that
the F clade could represent a unique ancestral isolate itself, which
was established from a geographically distinct region. The
appearance of clade F in Oregon, as well as the clade C isolate
in Colorado, may represent introduced, rather than endogenous,
virus. The FIV isolates used in this study were from both domestic
and feral cats. One possibility for these observations may be that
these isolates were obtained from domestic cats that had been
relocated by their owners. Relocation of a domestic FIV infected
cat from the southwest to the northwest would explain the clade F
in Oregon. Since clade C is typically found in Canada, the
relocation of a domestic FIV infected cat from Canada to
Colorado would explain the single clade C isolate. It is this
conclusion that lead researchers to believe that a clade A virus had
been introduced into the Japanese feline population from an
American or European country [28].
Data presented from this study indicate that FIV may form 6
genetically distinct viral clades. This makes FIV a much more
desirable model for HIV-1, which has been identified to have
nine clades [39]. As there is a lack of biological and clinical
analyses, there is no established correlation between clade and
pathogenesis. To date, however, there are only 3 viruses, two
clade A and one clade C, which have been shown to consistently
cause fatal immunodeficiency disease in cats under experimental
conditions and only one of these 3 has been molecularly cloned
[38,40,41].
The development of an effective HIV vaccine for worldwide use
may be modeled after FIV, which exemplifies the difficult
challenges inherent to lentiviral vaccines. The challenge of high
mutation rates, proviral DNA incorporation, viral reservoirs, and
the multi-cellular tissue tropism of FIV make it the most suitable
candidate model. Recently, a dual clade vaccine, consisting of a
clade A virus and a clade D virus, was developed. However, this
dual clade vaccine, which has been made commercially available
in the U.S.A. only represents one of the 4 possible clades and
provides limited immunity against cross clade challenge [34].
These phylogenetic studies may provide the tools necessary for
identifying candidate strains for vaccine development. This study
indicates that the current vaccine trials are negating the viral
divergence of FIV and the inclusion of the 4 viral clades may be
essential for creating a truly cross clade FIV vaccine capable of
protecting cats within the U.S.A. from natural challenge.
Supporting Information
Table S1 The FIV viral isolates, Genbank accession numbers
and the origin of the env sequences used for phylogenetic analyses
in this study.
Found at: doi:10.1371/journal.pone.0012004.s001 (0.09 MB
DOC)
Table S2 Sample descriptions and subtype analysis. a Subtype
was determined by heteroduplex mobility assay [24]. b Subtype
was determined based on the nucleotide sequence of the V3-V5
envelope region [31]. c Subtype was determined based on the
nucleotide sequence of the V3-V4 envelope region as determined
in this study.
Found at: doi:10.1371/journal.pone.0012004.s002 (0.15 MB
DOC)
Table 1. The Average percent nucleotide identity of the viral
isolates as compared to previously published and
characterized viral isolates.
Clade
Isolate A B C D E
A AK1 8.23 24.93 28.37 23.10 25.75
B CA1 3 25.39 9.99 24.66 20.57 20.37
A CA1 4 11.75 27.39 28.25 26.17 28.63
A CA1 6 6.88 24.01 25.04 21.72 23.15
B CA2 1 24.76 18.12 24.26 20.72 19.48
B CA2 2 24.21 7.95 20.71 18.71 17.23
A CA2 4 7.65 23.63 24.95 22.61 24.16
B IL1 8.75 27.94 27.40 26.29 26.32
B IL2 23.57 9.28 22.90 19.87 21.75
B IL3 22.79 5.31 21.73 18.50 17.03
B IL4 24.43 5.62 22.98 20.23 19.04
B IL5 23.00 5.19 22.70 19.65 17.75
B IL6 9.25 22.48 25.22 21.55 24.23
B IL7 25.29 5.79 23.43 20.56 19.29
B IL8 24.37 5.18 22.69 19.28 17.74
B MA1 26.51 12.34 23.28 20.40 17.02
B MA2 26.51 12.34 23.28 20.40 17.02
B MA3 25.59 14.13 23.35 18.78 18.87
B MA4 26.39 9.58 25.06 21.60 21.45
B MA5 26.39 9.58 25.06 21.60 21.45
B MA6 25.70 7.28 23.27 20.35 20.38
B MA7 24.39 14.63 21.31 19.52 15.29
A OR1 8.52 25.36 27.19 23.90 26.55
F OR2 25.58 15.40 24.86 22.78 19.96
A OR3 7.90 21.69 24.94 20.69 23.46
F TX77 24.28 14.49 24.00 22.04 18.47
F TX78 23.83 14.66 23.89 22.26 18.51
F TX84 25.15 15.78 25.27 23.00 19.89
F TX109 25.02 15.59 25.07 22.81 19.42
F TX120 23.92 14.90 23.75 21.78 18.23
F TX125 24.33 15.23 24.49 22.53 19.15
F TX132 25.13 16.68 24.73 23.21 17.08
F TX133 25.13 16.68 24.73 23.21 17.08
F TX200 24.82 17.21 25.08 23.68 17.09
F TXMK 26.26 16.33 25.63 24.49 19.73
F TXTG 26.78 16.43 27.42 23.40 20.10
F TXmtex 24.22 15.21 23.92 21.08 18.10
doi:10.1371/journal.pone.0012004.t001
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